A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

NCT04438083 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class

Stopped Patients to be followed up in the CRSP-ONC-LTF study

Conditions

Interventions

Sponsor

CRISPR Therapeutics AG